Voyxact savings card from the maker

How to pay the least

Ask for the cash price

Voyxact

Voyxact is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.

Ask your pharmacy for Voyxact’s cash price, and one or two other pharmacies too.

Free from the maker, if you qualify Otsuka Patient Assistance Foundation (OPAF). When you submit an application, please include proof of income for all members of the household who file a tax return. Or call 1-855-727-6274.

See if you qualify

Compare every option

Brand nameVoyxact

Authorized genericsibeprenlimab

Regular genericsibeprenlimab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Voyxact?

The original

–

Brand nameThe maker’s card

VOYXACT Copay Program (Otsuka Patient Services)

Savings card from Otsuka America Pharmaceutical

Voyxact’s maker has a savings program. Its page doesn’t list a dollar amount.

From the maker’s site, checked November 2, 2026. Check the maker’s page for who can use it.

Authorized genericNot sold

There isn’t one. An authorized generic is Voyxact itself, from the same company, sold without the brand name, and usually for less. For now Voyxact is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Voyxact is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

Lowering urine protein in IgA nephropathy (kidney disease)

What the FDA label says

VOYXACT is an A Proliferation Inducing Ligand (APRIL) blocker, indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether VOYXACT slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Source: the FDA label for Voyxact (Otsuka America Pharmaceutical, Inc.), March 17, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Check the maker’s page for who can use it.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/voyxact/